首页 > 最新文献

Global Medical Genetics最新文献

英文 中文
Analyzing Cell-free Genomic DNA in Spent Culture Media: Noninvasive Insight into the Blastocysts. 分析废培养基中的无细胞基因组 DNA:无创洞察囊胚。
IF 1.5 Q4 GENETICS & HEREDITY Pub Date : 2024-07-23 eCollection Date: 2024-09-01 DOI: 10.1055/s-0044-1788260
Siddhartha Shankar Layek, Shrushti Kanani, Shilpa Doultani, Tejas Gohil, Sanket Patil, Ananthasayanam Sudhakar, Kathan Banubhai Raval, Karuppanasamy Kuppusamy, Sanjay Gorani, Sudharson Raj, Rafiya Sangameshwari, Himali Jadeja, Mini Mol P

A commonly accepted standard protocol for noninvasive techniques for the genetic evaluation of an embryo remains elusive due to inconclusiveness regarding the volume of spent media to be acquired and the possibility of acquiring the same for subsequent analysis. Single embryo culture is imperative for standardizing noninvasive preimplantation testing using cell-free DNA (cf-DNA) released by individual developing embryos. This study aims to compare the development dynamics of single-drop embryonic culture against with group embryonic culture to establish a standardized protocol for noninvasive Preimplantation Genetic Testing (PGT) in bovine. A total of 239 cumulus-oocyte complexes were aspirated and subjected to in vitro maturation and fertilization. Among these, 120 embryos of day 3 were transferred to single-drop culture until the blastocyst stage. The single-drop culture drops were prepared using microdrops of 30 μL. At the blastocyst stage, spent media from all single-drop embryos were utilized for extracting cell-free genomic DNA to standardize the protocol. The blastocyst rate indicates no significant difference between the two culture methods, suggesting that single-drop culture is suitable for the process. Additionally, the extracted spent media yielded sufficient quantities of cf-DNA, supporting its potential use for PGT ( p  < 0.05). These findings support the hypothesis that single-drop embryo culture is a viable method for cf-DNA extraction and confirm the potential of using DNA fragments from spent media as a reliable source for noninvasive PGT.

对胚胎进行遗传评估的非侵入性技术,目前还没有一个公认的标准协议,原因是在获取用过的培养基量以及获取这些培养基用于后续分析的可能性方面还没有定论。单个胚胎培养对于利用单个发育中胚胎释放的无细胞 DNA(cf-DNA)进行标准化无创胚胎植入前检测至关重要。本研究旨在比较单滴胚胎培养与群体胚胎培养的发育动态,为牛的无创胚胎植入前遗传学检测(PGT)制定标准化方案。共抽取了 239 个积液-卵母细胞复合体,并对其进行体外成熟和受精。其中,第 3 天的 120 个胚胎被转移到单滴培养,直至囊胚期。单滴培养液是用 30 μL 的微滴配制的。在囊胚期,所有单滴胚胎的废培养基都用于提取无细胞基因组 DNA,以规范操作程序。囊胚率表明两种培养方法之间没有显著差异,这表明单滴培养适合该过程。此外,提取的废培养基产生了足够数量的 cf-DNA,支持其用于 PGT 的潜力(p
{"title":"Analyzing Cell-free Genomic DNA in Spent Culture Media: Noninvasive Insight into the Blastocysts.","authors":"Siddhartha Shankar Layek, Shrushti Kanani, Shilpa Doultani, Tejas Gohil, Sanket Patil, Ananthasayanam Sudhakar, Kathan Banubhai Raval, Karuppanasamy Kuppusamy, Sanjay Gorani, Sudharson Raj, Rafiya Sangameshwari, Himali Jadeja, Mini Mol P","doi":"10.1055/s-0044-1788260","DOIUrl":"10.1055/s-0044-1788260","url":null,"abstract":"<p><p>A commonly accepted standard protocol for noninvasive techniques for the genetic evaluation of an embryo remains elusive due to inconclusiveness regarding the volume of spent media to be acquired and the possibility of acquiring the same for subsequent analysis. Single embryo culture is imperative for standardizing noninvasive preimplantation testing using cell-free DNA (cf-DNA) released by individual developing embryos. This study aims to compare the development dynamics of single-drop embryonic culture against with group embryonic culture to establish a standardized protocol for noninvasive Preimplantation Genetic Testing (PGT) in bovine. A total of 239 cumulus-oocyte complexes were aspirated and subjected to in vitro maturation and fertilization. Among these, 120 embryos of day 3 were transferred to single-drop culture until the blastocyst stage. The single-drop culture drops were prepared using microdrops of 30 μL. At the blastocyst stage, spent media from all single-drop embryos were utilized for extracting cell-free genomic DNA to standardize the protocol. The blastocyst rate indicates no significant difference between the two culture methods, suggesting that single-drop culture is suitable for the process. Additionally, the extracted spent media yielded sufficient quantities of cf-DNA, supporting its potential use for PGT ( <i>p</i>  < 0.05). These findings support the hypothesis that single-drop embryo culture is a viable method for cf-DNA extraction and confirm the potential of using DNA fragments from spent media as a reliable source for noninvasive PGT.</p>","PeriodicalId":40142,"journal":{"name":"Global Medical Genetics","volume":"11 3","pages":"227-232"},"PeriodicalIF":1.5,"publicationDate":"2024-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11265834/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141752979","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
ABO Blood Type and Urinary Bladder Cancer: Phenotype, Genotype, Allelic Association with a Clinical or Histological Stage and Recurrence Rate. ABO 血型与膀胱癌:表型、基因型、等位基因与临床或组织学分期及复发率的关系
IF 1.5 Q4 GENETICS & HEREDITY Pub Date : 2024-07-22 eCollection Date: 2024-09-01 DOI: 10.1055/s-0044-1788614
Ivan Milas, Željko Kaštelan, Jószef Petrik, Jasna Bingulac-Popović, Bojan Čikić, Andrej Šribar, Irena Jukić

Background  Previous research on connection between the ABO blood group and bladder cancer has been based on determining the ABO phenotype. This specific research is extended to the molecular level, providing more information about particular ABO alleles. Aim  To investigate the impact of the ABO blood group genotype or phenotype as a risk factor for urinary bladder cancer. Materials and Methods  In the case-control study, we included 74 patients who underwent surgery for a urinary bladder tumor at the Urology Clinic, Clinical Hospital Centre Zagreb, in 2021 and 2022. The control group comprised 142 asymptomatic and healthy blood donors. ABO genotyping to five basic alleles was done using a polymerase chain reaction with sequence-specific primers. We compared ABO phenotypes, genotypes, and alleles between patients and the healthy controls and investigated their distribution according to the clinical and histological stage and recurrence rate. Results  No statistically significant difference was found among the groups, nor for the observed disease stages in terms of the phenotype and genotype. At the allele level, the results show a significantly lower proportion of malignancy in O1 ( p  < 0.001), A1 ( p  < 0.001), and B ( p  = 0.013), and a lower proportion of metastatic disease in A2 (0%, p  = 0.024). We also found significantly higher proportions of high-grade tumors in patients with O1 (71.4%, p  < 0.001), A1 (70.1%, p  = 0.019), of nonmuscle invasive tumors in patients with O1 (55.1%, p  < 0.001), O2 (100%, p  = 0.045), and recurrent tumors in patients with O1 (70.2%, p  < 0.001) and A1 (74.2%, p  = 0.007) alleles. Conclusion  We did not find an association between the ABO blood group genotype or phenotype as a genetic risk factor for urinary bladder cancer. However, an analysis at the allelic level revealed a statistically significant association between certain alleles of the ABO blood group system and urinary bladder tumors, clinical or histological stage, and recurrence rate, respectively.

背景以往关于 ABO 血型与膀胱癌之间关系的研究都是基于确定 ABO 血型的表型。这项特定研究扩展到了分子水平,提供了更多有关特定 ABO 等位基因的信息。目的 研究 ABO 血型基因型或表型作为膀胱癌风险因素的影响。材料与方法 在病例对照研究中,我们纳入了 74 名于 2021 年和 2022 年在萨格勒布临床医院中心泌尿科诊所接受膀胱肿瘤手术的患者。对照组包括 142 名无症状的健康献血者。利用聚合酶链反应和序列特异性引物对五种基本等位基因进行了 ABO 基因分型。我们比较了患者和健康对照组的 ABO 表型、基因型和等位基因,并根据临床和组织学分期以及复发率调查了它们的分布情况。结果 在表型和基因型方面,各组之间以及所观察到的疾病分期之间均未发现明显的统计学差异。在等位基因水平上,结果显示 O1 的恶性肿瘤比例明显较低(p p = 0.013),A2 的转移性疾病比例较低(0%,p = 0.024)。我们还发现,O1(71.4%,p p = 0.019)等位基因患者的高级别肿瘤比例、O1(55.1%,p p = 0.045)等位基因患者的非肌肉浸润性肿瘤比例和 O1(70.2%,p p = 0.007)等位基因患者的复发性肿瘤比例均明显较高。结论 我们没有发现 ABO 血型基因型或表型与膀胱癌遗传风险因素之间存在关联。然而,等位基因水平的分析表明,ABO 血型系统的某些等位基因分别与膀胱肿瘤、临床或组织学分期以及复发率之间存在统计学意义上的显著关联。
{"title":"ABO Blood Type and Urinary Bladder Cancer: Phenotype, Genotype, Allelic Association with a Clinical or Histological Stage and Recurrence Rate.","authors":"Ivan Milas, Željko Kaštelan, Jószef Petrik, Jasna Bingulac-Popović, Bojan Čikić, Andrej Šribar, Irena Jukić","doi":"10.1055/s-0044-1788614","DOIUrl":"10.1055/s-0044-1788614","url":null,"abstract":"<p><p><b>Background</b>  Previous research on connection between the ABO blood group and bladder cancer has been based on determining the ABO phenotype. This specific research is extended to the molecular level, providing more information about particular ABO alleles. <b>Aim</b>  To investigate the impact of the ABO blood group genotype or phenotype as a risk factor for urinary bladder cancer. <b>Materials and Methods</b>  In the case-control study, we included 74 patients who underwent surgery for a urinary bladder tumor at the Urology Clinic, Clinical Hospital Centre Zagreb, in 2021 and 2022. The control group comprised 142 asymptomatic and healthy blood donors. ABO genotyping to five basic alleles was done using a polymerase chain reaction with sequence-specific primers. We compared ABO phenotypes, genotypes, and alleles between patients and the healthy controls and investigated their distribution according to the clinical and histological stage and recurrence rate. <b>Results</b>  No statistically significant difference was found among the groups, nor for the observed disease stages in terms of the phenotype and genotype. At the allele level, the results show a significantly lower proportion of malignancy in O1 ( <i>p</i>  < 0.001), A1 ( <i>p</i>  < 0.001), and B ( <i>p</i>  = 0.013), and a lower proportion of metastatic disease in A2 (0%, <i>p</i>  = 0.024). We also found significantly higher proportions of high-grade tumors in patients with O1 (71.4%, <i>p</i>  < 0.001), A1 (70.1%, <i>p</i>  = 0.019), of nonmuscle invasive tumors in patients with O1 (55.1%, <i>p</i>  < 0.001), O2 (100%, <i>p</i>  = 0.045), and recurrent tumors in patients with O1 (70.2%, <i>p</i>  < 0.001) and A1 (74.2%, <i>p</i>  = 0.007) alleles. <b>Conclusion</b>  We did not find an association between the ABO blood group genotype or phenotype as a genetic risk factor for urinary bladder cancer. However, an analysis at the allelic level revealed a statistically significant association between certain alleles of the ABO blood group system and urinary bladder tumors, clinical or histological stage, and recurrence rate, respectively.</p>","PeriodicalId":40142,"journal":{"name":"Global Medical Genetics","volume":"11 3","pages":"233-240"},"PeriodicalIF":1.5,"publicationDate":"2024-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11262885/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141749257","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Bridging Innovation Research with Clinical Application: Clinical Trials at the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences. 创新研究与临床应用的桥梁:中国医学科学院血液病研究所的临床试验。
IF 1.5 Q4 GENETICS & HEREDITY Pub Date : 2024-07-12 eCollection Date: 2024-09-01 DOI: 10.1055/s-0044-1788572
Xiaochen Wang, Lijun Liu
{"title":"Bridging Innovation Research with Clinical Application: Clinical Trials at the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences.","authors":"Xiaochen Wang, Lijun Liu","doi":"10.1055/s-0044-1788572","DOIUrl":"10.1055/s-0044-1788572","url":null,"abstract":"","PeriodicalId":40142,"journal":{"name":"Global Medical Genetics","volume":"11 3","pages":"225-226"},"PeriodicalIF":1.5,"publicationDate":"2024-07-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11245325/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141617358","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
46 XX Ovotesticular Disorder of Sex Development with Gonadotropin-Releasing Hormone Receptor, Autosomal Recessive Heterozygous Missense Mutation and Autosomal Dominant Heterozygous Missense Mutation of the PROKR2 Gene: A Case Report. 46 XX卵巢性发育障碍伴促性腺激素释放激素受体、PROKR2基因常染色体隐性杂合子缺义突变和常染色体显性杂合子缺义突变:病例报告。
IF 1.5 Q4 GENETICS & HEREDITY Pub Date : 2024-07-09 eCollection Date: 2024-09-01 DOI: 10.1055/s-0044-1788060
Francesca Peranzoni, Roberto De Castro, Emilio Merlini, Yen Le Nguyen

True hermaphroditism is a disorder of sex development (DSD), accounting for less than 5% of all DSD cases, defined by the simultaneous presence of testicular tissue and ovarian tissue in the same individual. In the reported case, the patient presented two genetic mutations involved in the pathogenic pathway of the DSD condition associated with the clinical features of Kallmann syndrome (KS), a developmental disease that associates hypogonadotropic hypogonadism (HH), due to gonadotropin-releasing hormone deficiency, and anosmia, related to the absence or hypoplasia of the olfactory bulbs. Given the variable degree of hyposmia in KS, the distinction between KS and normosmic idiopathic HH is currently unclear, especially as HH patients do not always undergo detailed olfactory testing. This syndrome is very rare, with an estimated prevalence of 1:80,000 in males and 1:40,000 in females. This is the only case report concerning a patient with 46 XX true hermaphroditism affected by HH and digenic inheritance of Kallmann syndrome.

真两性畸形是一种性发育障碍(DSD),占所有DSD病例的不到5%,其定义是在同一个人体内同时存在睾丸组织和卵巢组织。在报告的病例中,患者出现了两种基因突变,涉及到与卡尔曼综合征(KS)临床特征相关的DSD病症的致病途径,卡尔曼综合征是一种发育疾病,与促性腺激素释放激素缺乏引起的性腺功能减退症(HH)和嗅觉减退症(与嗅球缺失或发育不良有关)相关。鉴于 KS 患者嗅觉减退的程度不一,目前尚不清楚如何区分 KS 和正常嗅觉的特发性 HH,尤其是 HH 患者并不总是接受详细的嗅觉测试。这种综合征非常罕见,男性发病率估计为 1:80000,女性为 1:40000。这是唯一一例有关 46 XX 真两性畸形患者受 HH 和 Kallmann 综合征二基因遗传影响的病例报告。
{"title":"46 XX Ovotesticular Disorder of Sex Development with Gonadotropin-Releasing Hormone Receptor, Autosomal Recessive Heterozygous Missense Mutation and Autosomal Dominant Heterozygous Missense Mutation of the <i>PROKR2</i> Gene: A Case Report.","authors":"Francesca Peranzoni, Roberto De Castro, Emilio Merlini, Yen Le Nguyen","doi":"10.1055/s-0044-1788060","DOIUrl":"10.1055/s-0044-1788060","url":null,"abstract":"<p><p>True hermaphroditism is a disorder of sex development (DSD), accounting for less than 5% of all DSD cases, defined by the simultaneous presence of testicular tissue and ovarian tissue in the same individual. In the reported case, the patient presented two genetic mutations involved in the pathogenic pathway of the DSD condition associated with the clinical features of Kallmann syndrome (KS), a developmental disease that associates hypogonadotropic hypogonadism (HH), due to gonadotropin-releasing hormone deficiency, and anosmia, related to the absence or hypoplasia of the olfactory bulbs. Given the variable degree of hyposmia in KS, the distinction between KS and normosmic idiopathic HH is currently unclear, especially as HH patients do not always undergo detailed olfactory testing. This syndrome is very rare, with an estimated prevalence of 1:80,000 in males and 1:40,000 in females. This is the only case report concerning a patient with 46 XX true hermaphroditism affected by HH and digenic inheritance of Kallmann syndrome.</p>","PeriodicalId":40142,"journal":{"name":"Global Medical Genetics","volume":"11 3","pages":"220-224"},"PeriodicalIF":1.5,"publicationDate":"2024-07-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11233268/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141581079","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Recurrent Cerebral Venous Sinus Thrombosis Occurred in an Acute Lymphoblastic Leukemia Child with Mutated Lipoprotein Lipase Gene during Asparaginase Therapy. 一名脂蛋白脂酶基因突变的急性淋巴细胞白血病患儿在接受天冬酰胺酶治疗期间出现复发性脑静脉窦血栓。
IF 1.5 Q4 GENETICS & HEREDITY Pub Date : 2024-07-05 eCollection Date: 2024-09-01 DOI: 10.1055/s-0044-1788043
Shiyuan Wang, Jun Li, Ying Li, Xiaoming Liu, Lixian Chang, Beibei Zhao, Li Zhang, Yao Zou, Min Ruan, Xiaofan Zhu

Cerebral venous sinus thrombosis (CVST) and hyperlipidemia are severe complications of L-Asparaginase (L-Asp) during the treatment of B-cell acute lymphoblastic leukemia (B-ALL). Herein, we reported a 9-year-old B-ALL boy who underwent abnormal hypertriglyceridemia and CVST presenting as seizures and disturbance of consciousness twice during the induction therapy. Fortunately, he survived treatment with anticoagulant and lipid-lowering therapy. No thrombophilia-related gene mutation was detected, but a heterozygous mutation in lipoprotein lipase (LPL) gene was identified. His neurological symptoms were managed with short-term anticoagulant therapy and long-term lipid-lowering therapy. This case illustrated the manifestation and potential pathogenesis of CVST and highlighted the essentiality of screening baseline lipid profile and dyslipidemia- and thrombophilia-related gene mutation.

脑静脉窦血栓(CVST)和高脂血症是天冬酰胺酶(L-Asp)治疗 B 细胞急性淋巴细胞白血病(B-ALL)期间的严重并发症。在此,我们报告了一名 9 岁的 B-ALL 男孩,他在诱导治疗期间两次出现异常的高甘油三酯血症和 CVST,表现为癫痫发作和意识障碍。幸运的是,他在接受抗凝和降脂治疗后存活了下来。虽然没有检测到血栓相关基因突变,但发现了脂蛋白脂肪酶(LPL)基因的杂合突变。他的神经症状通过短期抗凝治疗和长期降脂治疗得到了控制。该病例说明了 CVST 的表现和潜在发病机制,并强调了筛查基线血脂谱和血脂异常及血栓相关基因突变的重要性。
{"title":"Recurrent Cerebral Venous Sinus Thrombosis Occurred in an Acute Lymphoblastic Leukemia Child with Mutated Lipoprotein Lipase Gene during Asparaginase Therapy.","authors":"Shiyuan Wang, Jun Li, Ying Li, Xiaoming Liu, Lixian Chang, Beibei Zhao, Li Zhang, Yao Zou, Min Ruan, Xiaofan Zhu","doi":"10.1055/s-0044-1788043","DOIUrl":"10.1055/s-0044-1788043","url":null,"abstract":"<p><p>Cerebral venous sinus thrombosis (CVST) and hyperlipidemia are severe complications of L-Asparaginase (L-Asp) during the treatment of B-cell acute lymphoblastic leukemia (B-ALL). Herein, we reported a 9-year-old B-ALL boy who underwent abnormal hypertriglyceridemia and CVST presenting as seizures and disturbance of consciousness twice during the induction therapy. Fortunately, he survived treatment with anticoagulant and lipid-lowering therapy. No thrombophilia-related gene mutation was detected, but a heterozygous mutation in lipoprotein lipase (LPL) gene was identified. His neurological symptoms were managed with short-term anticoagulant therapy and long-term lipid-lowering therapy. This case illustrated the manifestation and potential pathogenesis of CVST and highlighted the essentiality of screening baseline lipid profile and dyslipidemia- and thrombophilia-related gene mutation.</p>","PeriodicalId":40142,"journal":{"name":"Global Medical Genetics","volume":"11 3","pages":"214-219"},"PeriodicalIF":1.5,"publicationDate":"2024-07-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11226343/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141555651","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Alarming Situation of Highly Pathogenic Avian Influenza Viruses in 2019-2023. 2019-2023 年高致病性禽流感病毒的严峻形势。
IF 1.5 Q4 GENETICS & HEREDITY Pub Date : 2024-06-28 eCollection Date: 2024-09-01 DOI: 10.1055/s-0044-1788039
Zhiwei Zhang, Zhao Lei

Avian influenza viruses (AIVs) have the potential to cause severe illness in wild birds, domestic poultry, and humans. The ongoing circulation of highly pathogenic avian influenza viruses (HPAIVs) has presented significant challenges to global poultry industry and public health in recent years. This study aimed to elucidate the circulation of HPAIVs during 2019 to 2023. Specifically, we assess the alarming global spread and continuous evolution of HPAIVs. Moreover, we discuss their transmission and prevention strategies to provide valuable references for future prevention and control measures against AIVs.

禽流感病毒 (AIV) 有可能导致野生鸟类、家禽和人类患上严重疾病。近年来,高致病性禽流感病毒(HPAIVs)的持续流行给全球家禽业和公共卫生带来了巨大挑战。本研究旨在阐明 2019 年至 2023 年期间高致病性禽流感病毒的流行情况。具体而言,我们评估了高致病性禽流感令人担忧的全球传播和持续演变。此外,我们还讨论了高致病性禽流感病毒的传播和预防策略,为未来针对禽流感病毒的防控措施提供有价值的参考。
{"title":"The Alarming Situation of Highly Pathogenic Avian Influenza Viruses in 2019-2023.","authors":"Zhiwei Zhang, Zhao Lei","doi":"10.1055/s-0044-1788039","DOIUrl":"10.1055/s-0044-1788039","url":null,"abstract":"<p><p>Avian influenza viruses (AIVs) have the potential to cause severe illness in wild birds, domestic poultry, and humans. The ongoing circulation of highly pathogenic avian influenza viruses (HPAIVs) has presented significant challenges to global poultry industry and public health in recent years. This study aimed to elucidate the circulation of HPAIVs during 2019 to 2023. Specifically, we assess the alarming global spread and continuous evolution of HPAIVs. Moreover, we discuss their transmission and prevention strategies to provide valuable references for future prevention and control measures against AIVs.</p>","PeriodicalId":40142,"journal":{"name":"Global Medical Genetics","volume":"11 3","pages":"200-213"},"PeriodicalIF":1.5,"publicationDate":"2024-06-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11213626/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141471428","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Mesenchymal Stem Cells in Clinical Trials for Immune Disorders. 间充质干细胞在免疫疾病临床试验中的应用。
IF 1.5 Q4 GENETICS & HEREDITY Pub Date : 2024-06-27 eCollection Date: 2024-09-01 DOI: 10.1055/s-0044-1788044
Zongjin Li, Zhibo Han, Zhong-Chao Han
{"title":"Mesenchymal Stem Cells in Clinical Trials for Immune Disorders.","authors":"Zongjin Li, Zhibo Han, Zhong-Chao Han","doi":"10.1055/s-0044-1788044","DOIUrl":"10.1055/s-0044-1788044","url":null,"abstract":"","PeriodicalId":40142,"journal":{"name":"Global Medical Genetics","volume":"11 3","pages":"196-199"},"PeriodicalIF":1.5,"publicationDate":"2024-06-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11210999/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141471427","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comparing Genomic Profiles of ALK Fusion-Positive and ALK Fusion-Negative Nonsmall Cell Lung Cancer Patients. 比较 ALK 融合阳性和 ALK 融合阴性非小细胞肺癌患者的基因组特征
IF 1.5 Q4 GENETICS & HEREDITY Pub Date : 2024-06-13 eCollection Date: 2024-06-01 DOI: 10.1055/s-0044-1787301
Wenchao Xia, Jing Yang, Hongbin Li, Ling Li, Jinfeng Liu

Background  Anaplastic lymphoma kinase ( ALK ) fusion events account for 3 to 7% of genetic alterations in patients with nonsmall cell lung cancer (NSCLC). This study aimed to explore the landscape of ALK fusion-positive and ALK fusion-negative in a large cohort of NSCLC patients. Methods  The formalin-fixed paraffin-embedded specimens of NSCLC patients who underwent next-generation sequencing from 2020 to 2023 in Yinfeng Gene Technology Co., Ltd. Clinical laboratory were included in this study. Results  In the current study, a total of 180 (3.20%) patients tested positive for ALK fusions in 5,622 NSCLC samples. Within the ALK -positive cohort, a total of 228 ALK fusions were identified. Furthermore, five novel ALK fusion partners, including DAB1-ALK , KCMF1-ALK , KIF13A-ALK , LOC643770-ALK , and XDH-ALK were identified. In cases with ALK fusion-positive, TP53 alterations were the most prevalent (26.3%), followed by CDKN2A (8.4%), epidermal growth factor receptor ( EGFR , 5.6%), and ALK (5.6%). By contrast, EGFR alterations were most prevalent (51%) in patients with ALK fusion-negative NSCLC, followed by TP53 (42.7%), KRAS (11.6%), and CDKN2A (11.3%). A total of 10 cases where ALK fusion co-occurred with EGFR mutations were also identified. Notably, the ALK fusion positivity rate was higher in younger patients ( p  < 0.0001) and in female patients ( p  = 0.0429). Additionally, positive ALK test results were more prevalent in patients with high programmed death-ligand 1 expression, especially when applying a 50% cutoff. Conclusions  Collectively, these findings offer valuable genomic insights that could inform the personalized clinical care of patients with NSCLC harboring ALK fusions within the context of precision medicine.

背景 在非小细胞肺癌(NSCLC)患者中,无性淋巴瘤激酶(ALK)融合事件占基因改变的3%至7%。本研究旨在探索一大批 NSCLC 患者中 ALK 融合阳性和 ALK 融合阴性的情况。方法 将 2020 年至 2023 年期间在银丰基因技术有限公司临床实验室进行新一代测序的 NSCLC 患者的福尔马林固定石蜡包埋标本纳入本研究。本研究纳入了在银丰基因技术有限公司临床实验室进行新一代测序的 2020 年至 2023 年 NSCLC 患者石蜡包埋标本。结果 在本次研究中,5622 份 NSCLC 样本中共有 180 例(3.20%)患者检测出 ALK 融合阳性。在ALK阳性组群中,共鉴定出228例ALK融合。此外,还发现了五种新的ALK融合伙伴,包括DAB1-ALK、KCMF1-ALK、KIF13A-ALK、LOC643770-ALK和XDH-ALK。在ALK融合阳性病例中,TP53改变最普遍(26.3%),其次是CDKN2A(8.4%)、表皮生长因子受体(EGFR,5.6%)和ALK(5.6%)。相比之下,在ALK融合阴性的NSCLC患者中,表皮生长因子受体的改变最为普遍(51%),其次是TP53(42.7%)、KRAS(11.6%)和CDKN2A(11.3%)。此外,还发现了10例ALK融合与表皮生长因子受体突变共存的病例。值得注意的是,年轻患者的ALK融合阳性率更高(P P = 0.0429)。此外,ALK检测阳性结果在程序性死亡配体1高表达的患者中更为普遍,尤其是当采用50%的临界值时。结论 总的来说,这些发现提供了宝贵的基因组学见解,可为精准医疗背景下携带 ALK 融合的 NSCLC 患者的个性化临床治疗提供参考。
{"title":"Comparing Genomic Profiles of <i>ALK</i> Fusion-Positive and <i>ALK</i> Fusion-Negative Nonsmall Cell Lung Cancer Patients.","authors":"Wenchao Xia, Jing Yang, Hongbin Li, Ling Li, Jinfeng Liu","doi":"10.1055/s-0044-1787301","DOIUrl":"10.1055/s-0044-1787301","url":null,"abstract":"<p><p><b>Background</b>  Anaplastic lymphoma kinase ( <i>ALK</i> ) fusion events account for 3 to 7% of genetic alterations in patients with nonsmall cell lung cancer (NSCLC). This study aimed to explore the landscape of <i>ALK</i> fusion-positive and <i>ALK</i> fusion-negative in a large cohort of NSCLC patients. <b>Methods</b>  The formalin-fixed paraffin-embedded specimens of NSCLC patients who underwent next-generation sequencing from 2020 to 2023 in Yinfeng Gene Technology Co., Ltd. Clinical laboratory were included in this study. <b>Results</b>  In the current study, a total of 180 (3.20%) patients tested positive for <i>ALK</i> fusions in 5,622 NSCLC samples. Within the <i>ALK</i> -positive cohort, a total of 228 <i>ALK</i> fusions were identified. Furthermore, five novel <i>ALK</i> fusion partners, including <i>DAB1-ALK</i> , <i>KCMF1-ALK</i> , <i>KIF13A-ALK</i> , <i>LOC643770-ALK</i> , and <i>XDH-ALK</i> were identified. In cases with <i>ALK</i> fusion-positive, <i>TP53</i> alterations were the most prevalent (26.3%), followed by <i>CDKN2A</i> (8.4%), epidermal growth factor receptor ( <i>EGFR</i> , 5.6%), and <i>ALK</i> (5.6%). By contrast, <i>EGFR</i> alterations were most prevalent (51%) in patients with <i>ALK</i> fusion-negative NSCLC, followed by <i>TP53</i> (42.7%), <i>KRAS</i> (11.6%), and <i>CDKN2A</i> (11.3%). A total of 10 cases where <i>ALK</i> fusion co-occurred with <i>EGFR</i> mutations were also identified. Notably, the <i>ALK</i> fusion positivity rate was higher in younger patients ( <i>p</i>  < 0.0001) and in female patients ( <i>p</i>  = 0.0429). Additionally, positive <i>ALK</i> test results were more prevalent in patients with high programmed death-ligand 1 expression, especially when applying a 50% cutoff. <b>Conclusions</b>  Collectively, these findings offer valuable genomic insights that could inform the personalized clinical care of patients with NSCLC harboring <i>ALK</i> fusions within the context of precision medicine.</p>","PeriodicalId":40142,"journal":{"name":"Global Medical Genetics","volume":"11 2","pages":"175-186"},"PeriodicalIF":1.5,"publicationDate":"2024-06-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11175831/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141318545","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinical and Molecular Characteristics of Megakaryocytes in Myelodysplastic Syndrome. 骨髓增生异常综合征中巨核细胞的临床和分子特征
IF 1.5 Q4 GENETICS & HEREDITY Pub Date : 2024-06-10 eCollection Date: 2024-06-01 DOI: 10.1055/s-0044-1787752
Fangxiu Luo, Jialu Zhao, Yubao Chen, Zhenping Peng, Ran An, Yeling Lu, Jiaming Li

Objective  Myelodysplastic syndrome (MDS) is a malignant clonal disorder of hematopoietic stem cells which is characterized by morphologic dysplasia. However, the pathological characteristics of megakaryocytes (MKs) in MDS patients with gene mutation are not well established. Methods  Bone marrow MK specimens from 104 patients with primary MDS were evaluated, and all patients were distributed into two groups according to gene mutation associated with functional MKs. The morphologic and cellular characteristics of MKs and platelets were recorded and compared. Results  The more frequently mutated genes in MDS patients were TUBB1 (11.54%), VWF (8.65%), NBEAL2 (5.77%), and the most common point mutation was TUBB1 p.(R307H) and p.(Q43P). Patients with MK mutation showed a decrease in adenosine diphosphate-induced platelet aggregation, high proportion of CD34 + CD61 + MKs (10.00 vs. 4.00%, p  = 0.012), and short overall survival (33.15 vs. 40.50 months, p  = 0.013). Further, patients with a higher percent of CD34 + CD61 + MKs (≧20.00%) had lower platelet counts (36.00 × 10 9 /L vs. 88.50 × 10 9 /L, p  = 0.015) and more profound emperipolesis ( p  = 0.001). By analyzing RNA-sequencing of MKs, differentially expressed mRNA was involved in physiological processes including platelet function and platelet activation, especially for MDS patients with high percent of CD34 + CD61 + MKs. The high levels of expression of CD62P, CXCL10, and S100A9 mRNA, shown by RNA sequencing, were validated by PCR assay. Conclusion  High proportion of CD34 + CD61 + MKs was a poor prognostic factor in MDS patients with MK mutation. CD62P, CXCL10, and S100A9 may be the potential targets to evaluate the molecular link between gene defects and platelet function.

骨髓增生异常综合征(MDS)是一种造血干细胞恶性克隆性疾病,以形态发育不良为特征。然而,基因突变的 MDS 患者巨核细胞(MK)的病理特征尚未明确。方法 评估了 104 例原发性 MDS 患者的骨髓 MK 标本,并根据与功能性 MK 相关的基因突变将所有患者分为两组。记录并比较骨髓造血干细胞和血小板的形态和细胞特征。结果 MDS患者中较常见的突变基因是TUBB1(11.54%)、VWF(8.65%)和NBEAL2(5.77%),最常见的点突变是TUBB1 p.(R307H) 和 p.(Q43P)。MK突变患者的二磷酸腺苷诱导的血小板聚集减少,CD34 + CD61 + MK比例高(10.00 vs. 4.00%,P = 0.012),总生存期短(33.15 vs. 40.50个月,P = 0.013)。此外,CD34 + CD61 + MKs比例较高(≧20.00%)的患者血小板计数较低(36.00 × 10 9 /L vs. 88.50 × 10 9 /L,p = 0.015),且糜烂程度更深(p = 0.001)。通过分析 MKs 的 RNA 序列,差异表达的 mRNA 参与了包括血小板功能和血小板活化在内的生理过程,尤其是对于 CD34 + CD61 + MKs 百分比较高的 MDS 患者。RNA 测序显示的 CD62P、CXCL10 和 S100A9 mRNA 的高水平表达通过 PCR 检测得到了验证。结论 CD34 + CD61 + MKs的高比例是MK突变的MDS患者的不良预后因素。CD62P、CXCL10和S100A9可能是评估基因缺陷与血小板功能之间分子联系的潜在靶点。
{"title":"Clinical and Molecular Characteristics of Megakaryocytes in Myelodysplastic Syndrome.","authors":"Fangxiu Luo, Jialu Zhao, Yubao Chen, Zhenping Peng, Ran An, Yeling Lu, Jiaming Li","doi":"10.1055/s-0044-1787752","DOIUrl":"10.1055/s-0044-1787752","url":null,"abstract":"<p><p><b>Objective</b>  Myelodysplastic syndrome (MDS) is a malignant clonal disorder of hematopoietic stem cells which is characterized by morphologic dysplasia. However, the pathological characteristics of megakaryocytes (MKs) in MDS patients with gene mutation are not well established. <b>Methods</b>  Bone marrow MK specimens from 104 patients with primary MDS were evaluated, and all patients were distributed into two groups according to gene mutation associated with functional MKs. The morphologic and cellular characteristics of MKs and platelets were recorded and compared. <b>Results</b>  The more frequently mutated genes in MDS patients were <i>TUBB1</i> (11.54%), <i>VWF</i> (8.65%), <i>NBEAL2</i> (5.77%), and the most common point mutation was <i>TUBB1</i> p.(R307H) and p.(Q43P). Patients with MK mutation showed a decrease in adenosine diphosphate-induced platelet aggregation, high proportion of CD34 <sup>+</sup> CD61 <sup>+</sup> MKs (10.00 vs. 4.00%, <i>p</i>  = 0.012), and short overall survival (33.15 vs. 40.50 months, <i>p</i>  = 0.013). Further, patients with a higher percent of CD34 <sup>+</sup> CD61 <sup>+</sup> MKs (≧20.00%) had lower platelet counts (36.00 × 10 <sup>9</sup> /L vs. 88.50 × 10 <sup>9</sup> /L, <i>p</i>  = 0.015) and more profound emperipolesis ( <i>p</i>  = 0.001). By analyzing RNA-sequencing of MKs, differentially expressed mRNA was involved in physiological processes including platelet function and platelet activation, especially for MDS patients with high percent of CD34 <sup>+</sup> CD61 <sup>+</sup> MKs. The high levels of expression of CD62P, CXCL10, and S100A9 mRNA, shown by RNA sequencing, were validated by PCR assay. <b>Conclusion</b>  High proportion of CD34 <sup>+</sup> CD61 <sup>+</sup> MKs was a poor prognostic factor in MDS patients with MK mutation. CD62P, CXCL10, and S100A9 may be the potential targets to evaluate the molecular link between gene defects and platelet function.</p>","PeriodicalId":40142,"journal":{"name":"Global Medical Genetics","volume":"11 2","pages":"187-195"},"PeriodicalIF":1.5,"publicationDate":"2024-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11164576/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141301807","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Identification of a Novel Intronic Mutation in VMA21 Associated with a Classical Form of X-Linked Myopathy with Autophagy. 发现一种新型 VMA21 非线性突变,该突变与伴有自噬的 X 连锁肌病的典型形式有关。
IF 1.5 Q4 GENETICS & HEREDITY Pub Date : 2024-05-10 eCollection Date: 2024-06-01 DOI: 10.1055/s-0044-1786815
Mainak Bardhan, Kiran Polavarapu, Dipti Baskar, Veeramani Preethish-Kumar, Seena Vengalil, Saraswati Nashi, Valakunja H Ganaraja, Dinesh Sharma, Karthik Kulanthaivelu, B N Nandeesh, Atchayaram Nalini

IntroductionVMA21 -related myopathy is one of the rare forms of slowly progressive myopathy observed in males. Till now, there have been only a handful of reports, mainly from Europe and America, and two reports from India. Method  Here, we describe a case of genetically confirmed VMA21 -associated myopathy with clinical, histopathological, and imaging features with a list of known VMA21 mutations. Results  A 29-year-old man had the onset of symptoms at 18 years of age with features of proximal lower limb weakness. Muscle magnetic resonance imaging showed the preferential involvement of vasti and adductor magnus. A biopsy of the left quadriceps femoris showed features of autophagic vacuolar myopathy with vacuoles containing granular eosinophilic materials. In targeted next-generation sequencing, hemizygous mutation in the 3' splice site of intron 2 of the VMA21 gene (c.164-7 T > A) was identified and confirmed the diagnosis of X-linked myopathy with excessive autophagy. Conclusion  This report expands the phenotypic and genotypic profile of VMA21 -related myopathy, with a yet unreported mutation in India.

导言 VMA21相关肌病是一种罕见的男性缓慢进展性肌病。迄今为止,只有少数几个主要来自欧洲和美国的报告,以及两个来自印度的报告。方法 我们在此描述了一例经基因证实的 VMA21 相关肌病,该病例具有临床、组织病理学和影像学特征,并列出了已知的 VMA21 基因突变。结果 一名 29 岁的男子在 18 岁时发病,表现为下肢近端无力。肌肉磁共振成像显示,该病优先累及腓肠肌和内收肌。左股四头肌的活组织检查显示了自噬空泡性肌病的特征,空泡中含有颗粒状嗜酸性物质。在有针对性的新一代测序中,VMA21基因内含子2的3'剪接位点(c.164-7 T > A)发生了半杂合子突变,确诊为伴有过度自噬的X连锁肌病。结论 本报告扩展了与 VMA21 相关的肌病的表型和基因型特征,其中的突变在印度尚未报道。
{"title":"Identification of a Novel Intronic Mutation in <i>VMA21</i> Associated with a Classical Form of X-Linked Myopathy with Autophagy.","authors":"Mainak Bardhan, Kiran Polavarapu, Dipti Baskar, Veeramani Preethish-Kumar, Seena Vengalil, Saraswati Nashi, Valakunja H Ganaraja, Dinesh Sharma, Karthik Kulanthaivelu, B N Nandeesh, Atchayaram Nalini","doi":"10.1055/s-0044-1786815","DOIUrl":"10.1055/s-0044-1786815","url":null,"abstract":"<p><p><b>Introduction</b>   <i>VMA21</i> -related myopathy is one of the rare forms of slowly progressive myopathy observed in males. Till now, there have been only a handful of reports, mainly from Europe and America, and two reports from India. <b>Method</b>  Here, we describe a case of genetically confirmed <i>VMA21</i> -associated myopathy with clinical, histopathological, and imaging features with a list of known VMA21 mutations. <b>Results</b>  A 29-year-old man had the onset of symptoms at 18 years of age with features of proximal lower limb weakness. Muscle magnetic resonance imaging showed the preferential involvement of vasti and adductor magnus. A biopsy of the left quadriceps femoris showed features of autophagic vacuolar myopathy with vacuoles containing granular eosinophilic materials. In targeted next-generation sequencing, hemizygous mutation in the 3' splice site of intron 2 of the <i>VMA21</i> gene (c.164-7 T > A) was identified and confirmed the diagnosis of X-linked myopathy with excessive autophagy. <b>Conclusion</b>  This report expands the phenotypic and genotypic profile of <i>VMA21</i> -related myopathy, with a yet unreported mutation in India.</p>","PeriodicalId":40142,"journal":{"name":"Global Medical Genetics","volume":"11 2","pages":"167-174"},"PeriodicalIF":1.5,"publicationDate":"2024-05-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11087142/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140910875","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Global Medical Genetics
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1